Volanesorsen
Sponsors
Ionis Pharmaceuticals, Inc., Akcea Therapeutics
Conditions
Abnormalities, CardiovascularFamilial ChylomicronemiaFamilial Chylomicronemia SyndromeFamilial Partial LipodystrophyHyperlipoproteinemia Type 1HypertriglyceridemiaLipoprotein Lipase Deficiency
Phase 1
Phase 2
Phase 3
The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
CompletedNCT02211209
Start: 2014-12-31End: 2017-03-28Updated: 2022-04-13
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
CompletedNCT02300233
Start: 2015-02-05End: 2017-01-24Updated: 2022-04-13
The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome
CompletedNCT02658175
Start: 2015-12-23End: 2020-01-15Updated: 2021-08-26